Market Access/ News/ News NICE backs BioCryst’s Orladeyo for hereditary angioedema Phil Taylor BioCryst Pharma, HEOR, hereditary angioedema, NICE, Orladeyo, rare disease 0 Comment BioCryst Pharma’s Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) Share X NICE backs BioCryst’s Orladeyo for hereditary angioedema https://pharmaphorum.com/news/nice-backs-biocrysts-orladeyo-for-hereditary-angioedema/